THE WOODLANDS, Texas, June 24, 2004 (PRIMEZONE) -- Power3 Medical Products, Inc. (OTCBB:PWRM) announces today they have filed for patents covering the 100 identified protein biomarkers used for the detection of early stage breast cancer with an additional filing for 30 protein biomarkers to follow. The Company utilizes proprietary technology and methodology to detect and identify, with unprecedented sensitivity, these biomarkers from nipple aspirate fluid (NAF). This proteomics technology was developed jointly with the MD Anderson Cancer Center in Houston Texas.
The NAF Test, the Company's initial breast cancer diagnostic test, analyzes fluids from the breast called nipple aspirates. The collection of the nipple aspirate is a non-invasive procedure to obtain a drop of fluid from the nipple. The aspirate is then analyzed to identify the specific breast cancer proteins. Power3's increasing portfolio of patent, patents-pending and trade secrets are delivering proteins that signal early stage breast cancer (pre-mammography) and have led to what the Company believes to be the first test of its type that detects breast cancer years earlier than current technology.
Dr. Ira Goldknopf, Chief Scientific Officer, Power3 Medical commented, "These identified protein biomarkers and mechanisms not only provide early indications of breast cancer but also reveal a mechanism for how the early breast cancer is developing. This discovery is fundamental to the Company's continuing efforts to identify new techniques for the detecting and treating of breast cancer in its earliest stage."
About Power3 Medical Products, Inc.
Power3 Medical Products is a leading edge biotechnology company engaged in the discovery of protein footprints, pathways, and mechanisms of diseases that the Company's proprietary technology can detect in patients. These discoveries are being used to develop screening and diagnostic tests for the early detection and treatment of disease. The protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. The Company is in a strong competitive position with over 250 identified biomarkers of human disease and operates a state-of-the-art proteomics laboratory in The Woodlands, Texas.
In addition, all current shareholders, and interested parties should sign into our private Corporate Guest Book, www.CorporateGuestBook.com/?PWRM to receive timely updates and information on future developments.
Safe Harbor Statement
All statements other than statements of historical fact included in this press release are "forward-looking statements." The forward-looking statements, including statements about the Company's future expectations, including future revenues and earnings, and all other forward-looking statements (i.e., future operational results and sales) are subject to assumptions and beliefs based on current information known to the Company and factors that are subject to uncertainties, risk and other influences, which are outside the Company's control, and may yield results differing materially from those anticipated.